1. Home
  2. IOVA vs KYN Comparison

IOVA vs KYN Comparison

Compare IOVA & KYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IOVA
  • KYN
  • Stock Information
  • Founded
  • IOVA 2007
  • KYN 2004
  • Country
  • IOVA United States
  • KYN United States
  • Employees
  • IOVA N/A
  • KYN N/A
  • Industry
  • IOVA Biotechnology: Biological Products (No Diagnostic Substances)
  • KYN Finance/Investors Services
  • Sector
  • IOVA Health Care
  • KYN Finance
  • Exchange
  • IOVA Nasdaq
  • KYN Nasdaq
  • Market Cap
  • IOVA 2.6B
  • KYN 2.2B
  • IPO Year
  • IOVA N/A
  • KYN N/A
  • Fundamental
  • Price
  • IOVA $5.82
  • KYN $12.82
  • Analyst Decision
  • IOVA Strong Buy
  • KYN
  • Analyst Count
  • IOVA 9
  • KYN 0
  • Target Price
  • IOVA $23.06
  • KYN N/A
  • AVG Volume (30 Days)
  • IOVA 7.2M
  • KYN 561.5K
  • Earning Date
  • IOVA 02-26-2025
  • KYN 01-01-0001
  • Dividend Yield
  • IOVA N/A
  • KYN 8.99%
  • EPS Growth
  • IOVA N/A
  • KYN N/A
  • EPS
  • IOVA N/A
  • KYN 0.71
  • Revenue
  • IOVA $90,858,000.00
  • KYN N/A
  • Revenue This Year
  • IOVA $13,803.28
  • KYN N/A
  • Revenue Next Year
  • IOVA $167.55
  • KYN N/A
  • P/E Ratio
  • IOVA N/A
  • KYN $13.79
  • Revenue Growth
  • IOVA 12751.20
  • KYN N/A
  • 52 Week Low
  • IOVA $5.05
  • KYN $7.84
  • 52 Week High
  • IOVA $18.33
  • KYN $9.88
  • Technical
  • Relative Strength Index (RSI)
  • IOVA 49.38
  • KYN 44.90
  • Support Level
  • IOVA $5.44
  • KYN $12.78
  • Resistance Level
  • IOVA $5.80
  • KYN $13.12
  • Average True Range (ATR)
  • IOVA 0.31
  • KYN 0.27
  • MACD
  • IOVA 0.09
  • KYN -0.05
  • Stochastic Oscillator
  • IOVA 82.43
  • KYN 18.80

About IOVA Iovance Biotherapeutics Inc.

Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.

About KYN Kayne Anderson Energy Infrastructure Fund Inc.

Kayne Anderson Energy Infrastructure Fund, Inc is a non-diversified, closed-end fund. Its investment objective is to provide a high after-tax total return with an emphasis on making cash distributions to the stockholder. The Company invests in various sectors, which include midstream energy companies, renewable infrastructure companies, and utility companies. The company seeks to achieve its objectives by investing a majority of its total assets in the securities of Energy Infrastructure companies.

Share on Social Networks: